A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Stopped Funder Decision
Conditions
- Metastatic Urothelial Cell Cancer
Interventions
- DRUG: Eribulin Mesylate
- DRUG: Avelumab
Sponsor
Monika Joshi, MD
Collaborators
- [object Object]
- [object Object]
- [object Object]